Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung Cancer

Recruiting now

Conditions studied: Lung Neoplasms

In brief

The mechanisms of sensitivity and resistance to oncogene-targeted therapy can be determined from tumor tissue or tumor cell lines derived from available archival samples and/or from standard-of-care re-biopsy upon suspected tumor progression.

Key facts

Study ID

NCT01580982

Run by

University of Colorado, Denver

People needed

500

Starts

2012-01-23

Expected to finish

2029-01-30

Last updated by the study team

2026-02-18

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients undergoing investigation or treatment for thoracic cancers with oncogene-targeted therapies
• Aged 18 years or older
• Either a) have suspected tumor progression or other condition that dictates a standard-of-care palliative, therapeutic, or diagnostic intervention including but not limited to procedures such as bronchoscopic biopsy, computed tomography (CT) or ultra-sound (US)-guided biopsy, thoracentesis, video assisted thoracoscopic (VATS) pleurodesis, lobectomy, adrenalectomy or pleural catheter placement, providing tumor specimen appropriate molecular analysis or b) have previously had biopsy/surgical intervention with tumor tissue at University of Colorado or an outside institution available for medullar analysis.
• Patients must have the ability to understand and willingness to sign an informed consent document.

Where it is running

• University of Colorado Cancer Center — Aurora, Colorado, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.